Antibody therapy for treatment of diseases associated with gluten intolerance
The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.
1. A method of treating celiac disease or dermatitis herpetiformis in a patient comprising administering to the patient, a therapeutically effective amount of a pharmaceutical composition comprising an isolated anti-gluten antibody and a pharmaceutically acceptable carrier wherein the anti-gluten antibody is specific for a toxic peptide from gluten wherein the toxic peptide derived from gluten is selected from the following α-gliadin peptides: LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 1); LGQQQPFPPQQPY (SEQ ID NO: 2); QLQPFPQPQLPY (SEQ ID NO: 3); LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4); and any combination thereof.
2. The method of claim 1 , wherein the composition is administered before ingesting a substance that may contain gluten or concurrently with the ingestion of a substance that may contain gluten.
3. The method of claim 1 , wherein the composition is administered after ingesting a substance that may contain gluten.
4. The method of claim 1 , wherein the composition is administered on a regular dosing schedule.
5. The method of claim 1 , wherein the anti-gluten antibody is present in the composition in a dosage range of 1 mg/kg-500 mg/kg body weight per dose.
6. The method of claim 1 , wherein the anti-gluten antibody is isolated from milk or colostrum.
7. The method of claim 6 , wherein the antibody is isolated from the milk or colostrum of a cow, a goat or a sheep.
8. The method of claim 1 , wherein the composition is formulated for oral delivery to the patient.
9. A method of treating celiac disease or dermatitis herpetiformis in a patient comprising administering to the patient, a therapeutically effective amount of a pharmaceutical composition comprising an anti-gluten antibody and a pharmaceutically acceptable carrier wherein the antibody is isolated from milk or colostrum of a ruminant selected from a cow, a goat and a sheep that has been immunized with an adjuvant in combination with gluten, gliadin, glutenin, a gluten derived peptide or any combination thereof and wherein the gluten-derived peptide is selected from the following α-gliadin peptides: LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 1); LGQQQPFPPQQPY (SEQ ID NO: 2); QLQPFPQPQLPY (SEQ ID NO: 3); LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4); and any combination thereof.
10. The method of claim 9 , wherein the glutamine residues in the gluten, gliadin, glutenin or gluten-derived peptide have been partially or fully deamidated prior to immunization of the ruminant used to generate the anti-gluten antibody.
11. The method of claim 9 , wherein the composition is formulated for oral delivery to a patient.
12. A method of treating celiac disease or dermatitis herpetiformis in a patient comprising administering to the patient, a therapeutically effective amount of a pharmaceutical composition comprising an anti-gluten antibody and a pharmaceutically acceptable carrier wherein the antibody is isolated from milk or colostrum and wherein the anti-gluten antibody is specific for a toxic peptide from gluten wherein the toxic peptide derived from gluten is selected from the following α-gliadin peptides: LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 1); LGQQQPFPPQQPY (SEQ ID NO: 2); QLQPFPQPQLPY (SEQ ID NO: 3); LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4); and any combination thereof.
13. The method of claim 12 , wherein the composition is formulated for oral delivery to the patient.
14. The method of claim 12 , wherein the antibody is isolated from the milk or colostrum of a cow, a goat or a sheep.